<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Allena Pharmaceuticals, Inc.

    Allena Pharmaceuticals, Inc.

    Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...

    Allena’s lead product candidate, reloxaliase,...

    Filing Type:    PU
    NeuBase Therapeutics, Inc.

    NeuBase Therapeutics, Inc.

    NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...

    NeuBase Therapeutics, Inc. is developing its mo...

    Filing Type:    PU
    BioHealthonomics Inc.

    BioHealthonomics Inc.

    BioHealthonomics Inc. is a research and development biotechnology & healthcare com...

    BioHealthonomics Inc. is a research and develop...

    Amount Raised:    $35,800
    Fundraising Status:    EC
    Filing Type:    CF
    Simulations Plus, Inc.

    Simulations Plus, Inc.

    Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...

    Simulations Plus, Inc. is the leading developer...

    Filing Type:    PU
    CohBar, Inc.

    CohBar, Inc.

    CohBar, Inc. is a leader in the research and development of mitochondria based the...

    CohBar, Inc. is a leader in the research and de...

    Filing Type:    PU
    Oramed Pharmaceuticals Inc.

    Oramed Pharmaceuticals Inc.

    Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...

    Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...

    Filing Type:    PU
    Leap Therapeutics, Inc.

    Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...

    Leap Therapeutics (NASDAQ: LPTX) is focused on ...

    Filing Type:    PU
    CTI BioPharma Corp.

    CTI BioPharma Corp.

    CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...

    CTI BioPharma is a biopharmaceutical company fo...

    Filing Type:    PU
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...

    Arena Pharmaceuticals is driven to deliver nove...

    Filing Type:    PU
    Five Prime Therapeutics, Inc.

    Five Prime Therapeutics, Inc.

    Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...

    Five Prime Therapeutics, Inc. discovers and dev...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.